Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the

Main measures

• The primary endpoint is the total number of Gd-enhancing lesions over four scans at Weeks 12,16,20 and 24 (calculated as the sum of these four MRI scans).

  MRI lesions

• A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dime

  Phase 3 · Not yet recruiting

  Still running

• Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting

  Phase 3 · Not yet recruiting

  Still running

• Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

  Recruiting

  Still running

• Observational Study of Persistence on Bafiertam Treatment in Routine C

  Stopped early

  Stopped

• A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Scle

  Phase 4 · Completed

  No results found

• Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Di

  Running, not recruiting

  Still running

1. Oct 2026In scope changed from true to false

1. Started

   Aug 2004